Myfortic (Mycophenolic Acid)

Mycophenolic acid inhibits the enzyme inosine monophosphate dehydrogenase, which is essential for the synthesis of guanosine nucleotides. This blocks the proliferation of activated T and B lymphocytes, reducing the immune response that can attack a transplanted organ.

The appropriate dose of Myfortic is individualized by the prescribing physician based on factors such as the type of transplant, the patient’s renal function, concomitant immunosuppressants, and therapeutic drug monitoring results.

Data on Myfortic use in pregnancy and lactation are limited. Because animal studies suggest potential risk to the fetus, it is generally avoided unless the benefits clearly outweigh the risks. Breastfeeding is not recommended without medical guidance.

To request Myfortic, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Myfortic (mycophenolic acid) is an antimetabolite that selectively targets lymphocyte proliferation, whereas drugs like tacrolimus or cyclosporine act on calcineurin pathways. Myfortic often has a different side‑effect profile, with fewer nephrotoxic concerns but a higher incidence of gastrointestinal symptoms.

Store Myfortic tablets at room temperature, below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged.

Myfortic is taken orally, usually with food to improve tolerability. The tablets are swallowed whole with a glass of water and should be taken at the same times each day as directed by the healthcare provider.

Serious risks include severe infections due to immunosuppression, bone‑marrow suppression leading to leukopenia or anemia, and liver injury reflected by elevated transaminases. Patients should be monitored regularly for these complications.

Myfortic is contraindicated in patients with known hypersensitivity to mycophenolic acid or any tablet excipients, and in individuals with uncontrolled severe infections. Caution is also advised for patients with significant renal or hepatic impairment.